Biosimilars
FDA Greenlights Biocon Biologics and Biogen’s Eylea Biosimilars: A New Era in Ophthalmology
FDA, Eylea, biosimilars, Biocon Biologics, Biogen, ophthalmology, aflibercept, regulatory approval
Cigna’s Evernorth Pushes for Increased Humira Biosimilar Adoption
Cigna, Evernorth, Humira, biosimilars, healthcare, pharmacy services, cost savings, patient access, AbbVie
Sandoz Wins Historic FDA Approval for First Two Interchangeable Denosumab Biosimilars Targeting Amgen’s Blockbuster Bone Therapy
Sandoz, FDA approval, Denosumab biosimilars, Wyost, Jubbonti, Interchangeable, Prolia, Xgeva, Amgen, Osteoporosis, Bone metastases, Cancer-related skeletal events, Patent litigation
Interchangeable Humira Biosimilar Simlandi Joins Market Battle with Unique High-Concentration Formula
Simlandi, interchangeable, Biosimilars, Market